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after hematopoietic stem cell transplantation (HSCT)
for hematologic malignancy. Targeting posttransplant
minimal residual disease with antigen-specific immu-
nologic effector cells is an attractive strategy to consol-
idate or augment the antitumor effect of the transplant
preparative regimen. Endowing T cells with tumor
specificity by genetic modification is one approach to
generating effector cells for posttransplant cellular
immunotherapy. To target malignant B cells of lym-
phoma and leukemia, we have constructed chimeric
immunoreceptors specific for B cell lineage markers
by fusing CD20- and CD19-specific single chain anti-
body (scFvFc) domains to the intracellular sequence of
the T cell receptor (TCR) complex’s zeta chain
(scFvFc:z) as well as fusion domains of CD28 and
CD28:4:1BB costimulatory domains in frame with
TCR zeta These antibody-based chimeric receptors
bind to epitopes on native cell-surface CD20 and
CD19, and thus are non-major histocompatibility
complex (MHC) restricted and can be applied to pop-
ulations of patients irrespective of their individual
HLAmakeup. Our laboratory has focused on studying
the immunobiology of T cells engineered to express
these receptors, as well as on the development of these
technologies for clinical deployment.
Our initial clinical trials investigated the use of
autologous CD20-specific CD81 CTL clones to treat
intermediate grade CD201 diffuse large-cell lympho-
mas and the use of autologous CD19-specific poly-
clonal T cells to treat follicular lymphoma. These
trials demonstrated that limited in vivo persistence
of the transferred effector cells was a significant obsta-
cle to therapeutic efficacy. Whether infused proximal
to a myeloablative HCT or after a course of fludara-
bine, the adoptively transferred T-cells persisted for
\7 days as measured by Q-PCR for vector sequences.
Short persistence could be attributed to antitransgene
immune responses in only a minority of patients (3 of10). The basis for the short persistence of CD81T cell
clones and oligoclonal T cell lines may be multifacto-
rial, but includes the possibility that intrinsic pro-
perties of engineered T cells might influence their
capacity to survive. Based on recent findings that effec-
tor cells derived from central memory T cells (TCM)
exhibit a greater capacity to persist after adoptive
transfer and respond to antigen, we have focused
recent efforts on introducing the chimeric antitumor
immunoreceptors into virus-specific central memory
T cells and are modeling the behavior of bispecific
antiviral  antitumor CAR grafted cells in model sys-
tems of adoptive T cell therapy. Our studies have
confirmed the superior engraftment potential of
TCM-derived effector cells in xenograft NOD-SCID
gamma-c knockout mice. Additionally, these studies
have demonstrated the capacity of antigen-presenting
cells (APC) expressing viral antigens to drive the fur-
ther expansion of these cells in vivo, and the capacity
of dual specific effectors to expand in response to
TCR ligation and mediate tumor clearance through
the grafted antitumor CARs.
We are developing an ex vivo system for the rapid
acquisition and engineering of virus-specific TCM that
permits the isolation of therapeutically relevant
numbers of bispecific T cells in 21 days, and is amena-
ble to GMP production. Our group is in the final
stages of manufacturing and release testing the clini-
cal-grade reagents to make this platform operational
for IND-supported clinical applications. A major
new application of this technology will be toward
the augmentation of graft-versus-leukemia (GVL) ef-
fect following allogeneic HCT for CD191 acute lym-
phoblastic leukemias (ALL) and to explore the
therapeutic application of autologous HCT in combi-
nation with adoptive transfer of CD19-specific effec-
tors for therapy of ALL patients without allogeneic
donors or who have contraindications to allogeneic
HCT.5
